Patents by Inventor Shuta Tomida
Shuta Tomida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124571Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.Type: ApplicationFiled: November 17, 2023Publication date: April 18, 2024Applicant: National University Corporation Okayama UniversityInventors: Masakiyo SAKAGUCHI, Shinichi TOYOOKA, Shuta TOMIDA, Kazuhiko SHIEN, Hiroki SATO, Rie KINOSHITA, Junichiro FUTAMI, Kota ARAKI, Mikio OKAZAKI, Eisaku KONDO, Yusuke INOUE, Akira YAMAUCHI
-
Publication number: 20240117446Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.Type: ApplicationFiled: June 30, 2023Publication date: April 11, 2024Inventors: Huiying Li, Shuta Tomida, Robert L. Modlin, Jeffery F. Miller, Sorel T. Fitz-Gibbon
-
Patent number: 11858984Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.Type: GrantFiled: April 15, 2019Date of Patent: January 2, 2024Assignees: National University Corporation Okayama University, Niigata University, National University Corporation Gunma UniversityInventors: Masakiyo Sakaguchi, Shinichi Toyooka, Shuta Tomida, Kazuhiko Shien, Hiroki Sato, Rie Kinoshita, Junichiro Futami, Kota Araki, Mikio Okazaki, Eisaku Kondo, Yusuke Inoue, Akira Yamauchi
-
Patent number: 11692229Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.Type: GrantFiled: September 25, 2020Date of Patent: July 4, 2023Assignee: The Regents of the University of CaliforniaInventors: Huiying Li, Shuta Tomida, Robert L. Modlin, Jeffery F. Miller, Sorel T. Fitz-Gibbon
-
Publication number: 20210123092Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.Type: ApplicationFiled: September 25, 2020Publication date: April 29, 2021Inventors: Huiying Li, Shuta Tomida, Robert L. Modlin, Jeffery F. Miller, Sorel T. Fitz-Gibbon
-
Publication number: 20210054061Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.Type: ApplicationFiled: April 15, 2019Publication date: February 25, 2021Applicants: National University Corporation Okayama University, NIIGATA UNIVERSITY, National University Corporation Gunma University, Kawasaki Gakuen Educational FoundationInventors: Masakiyo SAKAGUCHI, Shinichi TOYOOKA, Shuta TOMIDA, Kazuhiko SHIEN, Hiroki SATO, Rie KINOSHITA, Junichiro FUTAMI, Kota ARAKI, Mikio OKAZAKI, Eisaku KONDO, Yusuke INOUE, Akira YAMAUCHI
-
Publication number: 20190316183Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.Type: ApplicationFiled: April 22, 2019Publication date: October 17, 2019Inventors: Huiying Li, Shuta Tomida, Robert L. Modlin, Jeffery F. Miller, Sorel T. Fitz-Gibbon
-
Patent number: 10364473Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.Type: GrantFiled: September 6, 2016Date of Patent: July 30, 2019Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Huiying Li, Shuta Tomida, Robert L. Modlin, Jeffery F. Miller, Sorel T. Fitz-Gibbon
-
Publication number: 20170058328Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.Type: ApplicationFiled: September 6, 2016Publication date: March 2, 2017Inventors: Huiying Li, Shuta Tomida
-
Publication number: 20150086581Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.Type: ApplicationFiled: March 15, 2013Publication date: March 26, 2015Inventors: Huiying Li, Shuta Tomida
-
Patent number: 8710022Abstract: The present inventors revealed a TTF-1-specific oncogenic process by elucidating the molecular mechanism regulated by the master regulatory factor TTF-1. The present inventors focused on the elucidation of the essence of the lineage-specific survival signal which is a novel canceration signal. Thus, the present inventors found that the expression of ROR1, which is a receptor tyrosine kinase, is induced by the master regulatory factor TTF-1, and demonstrated the presence of a characteristic canceration signal transduction system.Type: GrantFiled: July 17, 2009Date of Patent: April 29, 2014Assignee: National University Corporation Nagoya UniversityInventors: Takashi Takahashi, Tomoya Yamaguchi, Shuta Tomida
-
Publication number: 20120082986Abstract: The present inventors revealed a TTF-1-specific oncogenic process by elucidating the molecular mechanism regulated by the master regulatory factor TTF-1. The present inventors focused on the elucidation of the essence of the lineage-specific survival signal which is a novel canceration signal. Thus, the present inventors found that the expression of ROR1, which is a receptor tyrosine kinase, is induced by the master regulatory factor TTF-1, and demonstrated the presence of a characteristic canceration signal transduction system.Type: ApplicationFiled: July 17, 2009Publication date: April 5, 2012Applicant: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITYInventors: Takashi Takahashi, Tomoya Yamaguchi, Shuta Tomida